SEC 13F Intelligence

Managers / Q2 2024 · view latest →

Cormorant Asset Management, LP

CIK 0001583977 · 200 CLARENDON STREET, 52ND FLOOR, BOSTON, MA, 02116 · 857-702-0388

Reported Value
$1.7B
Q2 2024
Positions
49
Filings on Record
30
2019–present window
Filed
Aug 14, 2024
original filing

Summary

Cormorant Asset Management, LP reported $1.7B in U.S.-listed holdings across 49 positions for Q2 2024.

The portfolio is heavily concentrated: MLTX alone accounts for 21.6% of reported value.

Compared with Q1 2024, the fund opened 10 new positions and exited 18.

Portfolio Metrics

Turnover
+19.2%
vs prior filed quarter
Top-10 Concentration
+58.5%
share of reported value
Largest Position
+21.6%
Moonlake Immunotherapeutics
New / Exited
10 / 18
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $1.2BQ4 ’18Q1 ’19: $1.5BQ2 ’19: $1.7BQ3 ’19: $1.6BQ4 ’19: $2.5BQ4 ’19Q1 ’20: $2.2BQ2 ’20: $2.6BQ3 ’20: $2.6BQ4 ’20: $4.2BQ4 ’20Q1 ’21: $4.5BQ2 ’21: $2.9BQ3 ’21: $2.5BQ4 ’21: $1.7BQ4 ’21Q1 ’22: $1.3BQ2 ’22: $1.3BQ3 ’22: $1.4BQ1 ’23: $2MQ1 ’23Q3 ’23: $1.7BQ4 ’23: $2.1BQ1 ’24: $2.3BQ2 ’24: $1.7BQ2 ’24Q3 ’24: $1.9BQ4 ’24: $1.8BQ1 ’25: $1.3BQ2 ’25: $1.3BQ2 ’25Q3 ’25: $1.4BQ4 ’25: $2.2BQ1 ’26: $2.0Bfilingsflow.com

Portfolio Composition

By security type
Common Stock: 79.1%Other: 17.7%ADR: 3.2%
  • Common Stock · 79.1% · $1.4B
  • Other · 17.7% · $307M
  • ADR · 3.2% · $55M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2024 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
RAPPRAPPORT THERAPEUTICS INCNEW+2.94M2.94M+$68M$68M
AXSMAXSOME THERAPEUTICS INCNEW+400.0K400.0K+$32M$32M
ALMSALUMIS INCNEW+2.15M2.15M+$29M$29M
UROGEN PHARMA LTDNEW+1.65M1.65M+$28M$28M
SRPTSAREPTA THERAPEUTICS INCNEW+125.0K125.0K+$20M$20M
CGEMCULLINAN THERAPEUTICS INCNEW+1.13M1.13M+$20M$20M
YMABUSDY-MABS THERAPEUTICS INCNEW+1.45M1.45M+$18M$18M
RNAGBPAVIDITY BIOSCIENCES INCNEW+425.0K425.0K+$17M$17M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2024

47 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1MLTXMOONLAKE IMMUNOTHERAPEUTICShistory →CLASS A ORD21.58%$373M8.49M
2CRBPCORBUS PHARMACEUTICALS HLDGShistory →COM NEW5.29%$92M2.02M
3ACLXGBXARCELLX INChistory →COMMON STOCK4.86%$84M1.52M
4PCVXVAXCYTE INChistory →COM4.80%$83M1.10M
5LONGBOARD PHARMACEUTICALS INCOM4.36%$75M2.79M
6EYPTEYEPOINT PHARMACEUTICALS INChistory →COM NEW4.18%$72M8.32M
7RAPPRAPPORT THERAPEUTICS INChistory →COM3.95%$68M2.94M
8CRNXCRINETICS PHARMACEUTICALS INhistory →COM3.49%$60M1.35M
9EWTXEDGEWISE THERAPEUTICS INChistory →COM3.13%$54M3.01M
10MERUS N VCOM2.87%$50M840.0K
11BBIOBRIDGEBIO PHARMA INChistory →COM2.72%$47M1.86M
12IM8NINSMED INChistory →COM PAR $.012.61%$45M675.0K
13NEWAMSTERDAM PHARMA COMPANYORDINARY SHARES2.55%$44M2.30M
14JANXJANUX THERAPEUTICS INChistory →COM2.54%$44M1.05M
15AXSMAXSOME THERAPEUTICS INChistory →COM1.86%$32M400.0K
16CGONCG ONCOLOGY INChistory →COM1.78%$31M975.0K
17HELIX ACQUISITION CORP IICL A ORD SHS1.72%$30M2.91M
18ALMSALUMIS INChistory →COM1.65%$29M2.15M
19PRAXPRAXIS PRECISION MEDICINES Ihistory →COM NEW1.64%$28M685.0K
20ABVXABIVAX SAhistory →SPONSORED ADS1.63%$28M2.13M
21BIOHAVEN LTDCOM1.61%$28M802.0K
22UROGEN PHARMA LTDCOM1.60%$28M1.65M
23PHARVARIS N VCOM1.59%$28M1.47M
24ARQTARCUTIS BIOTHERAPEUTICS INChistory →COM1.36%$23M2.52M
25SRPTSAREPTA THERAPEUTICS INChistory →COM1.14%$20M125.0K
26CGEMCULLINAN THERAPEUTICS INChistory →COM1.13%$20M1.13M
27RYTMRHYTHM PHARMACEUTICALS INChistory →COM1.13%$20M475.0K
28CRGXCARGO THERAPEUTICS INChistory →COM1.12%$19M1.18M
29YMABUSDY-MABS THERAPEUTICS INChistory →COM1.01%$18M1.45M
30RNAGBPAVIDITY BIOSCIENCES INChistory →COM1.00%$17M425.0K
31BMEABIOMEA FUSION INChistory →COM0.93%$16M3.57M
32260CENTESSA PHARMACEUTICALS PLChistory →SPONSORED ADS0.84%$15M1.61M
33TARSTARSUS PHARMACEUTICALS INChistory →COM0.79%$14M500.0K
34SLNSILENCE THERAPEUTICS PLChistory →ADS0.69%$12M625.0K
35AVBPARRIVENT BIOPHARMA INCCOM0.55%$10M515.0K
36ENGENE HOLDINGS INCCOM0.54%$9M1.00M
37KRROKORRO BIO INCCOM0.52%$9M265.8K
38IDYAIDEAYA BIOSCIENCES INCCOM0.50%$9M245.0K
39GH RESEARCH PLCORDINARY SHARES0.40%$7M593.0K
40LNTHLANTHEUS HLDGS INCCOM0.35%$6M75.0K
41STOKSTOKE THERAPEUTICS INCCOM0.33%$6M427.2K
42MERSANA THERAPEUTICS INCCOM0.30%$5M2.60M
43NGNENEUROGENE INCCOM0.23%$4M107.3K
44VYNEVYNE THERAPEUTICS INCCOM0.16%$3M1.39M
45CMPXCOMPASS THERAPEUTICS INCCOM0.12%$2M2.03M
46VERVE THERAPEUTICS INCCOM0.10%$2M350.0K
47RAPT THERAPEUTICS INCCOM0.09%$2M496.8K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$2.0B47May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$2.2B35Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$1.4B36Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$1.3B42Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$1.3B44May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$1.8B48Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$1.9B45Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$1.7B49Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$2.3B57May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$2.1B48Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$1.7B49Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023Under review64Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$2M72May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022Under review73Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$1.4B73Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$1.3B80Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$1.3B77May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$1.7B78Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$2.5B88Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$2.9B104Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$4.5B120May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$4.2B105Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$2.6B93Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$2.6B81Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$2.2B73May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$2.5B67Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$1.6B75Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$1.7B72Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$1.5B64May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$1.2B70Feb 14, 201913F-HRchanges · EDGAR ↗

Other Included Managers

This filing reports holdings on behalf of 1 additional manager.

  • Chen Bihua028-15950

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.